comprehensive -WSS

comprehensive

author：explore 2025-09-30 23:38:37 - browse：9

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

WSS

CDC says it’s too soon to assess risk posed by Covid subvariant

As obesity drug market grows, telehealth companies court payers

Kellogg’s is going to war over Mexico’s nutrition label rules

New Covid vaccine is recommended for everyone 6 months or older

Health officials lay out plans to cope with respiratory virus season

IRA could hurt research into orphan drugs for rare diseases

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

ChatGPT in medicine: STAT answers readers' burning questions

FDA panel endorses Alnylam’s heart drug — after picking it apart

Moonlake's readout produced a cash windfall. Risks remain

FDA approves updated Covid vaccines

Guidelines to prevent youth baseball injuries need more muscle

Listen: Vivek Ramaswamy's star turn & leaky drug data

The high cost of giving birth even with insurance

People can get long Covid without testing positive for virus: Study

entertainment

Popular nasal decongestant doesn't actually relieve congestion

Telehealth for opioid use disorder is lifesaving

How the first Native Hawaiian psychiatrist helped diversify medicine

Kellogg’s is going to war over Mexico’s nutrition label rules

Wegovy improves function in certain heart failure patients

As obesity drug market grows, telehealth companies court payers

knowledge

hotspot

knowledge

explore